Pulmonary disease, chronic obstructive Trials in Fukuoka, Japan
Conditions / Pulmonary disease, chronic obstructive / Fukuoka, Japan
Research into Pulmonary disease, chronic obstructive spans multiple therapeutic approaches and trial phases.
20 total trials for this combination
Showing top 10 of 20 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04072887 | Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients | COMPLETED | PHASE2 |
| NCT01543919 | Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide | COMPLETED | PHASE2 |
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT01313637 | A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD | COMPLETED | PHASE3 |
| NCT02105974 | Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT01053988 | A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT02105961 | Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT01054885 | Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT02729051 | Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT02164513 | A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |